ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1729

Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database

Ryoko Sakai1, Eiichi Tanaka2, Eisuke Inoue3, Minako Sato4, Masaru Tanaka4, Katsunori Ikari1, Atsuo Taniguchi1, Hisashi Yamanaka5 and Masayoshi Harigai6, 1Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 2Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 3Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, 4Eli Lilly Japan K.K., Tokyo, Japan, 5Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, 6Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan

Meeting: ACR Convergence 2020

Keywords: Cohort Study, Disability, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Disease burden and subjective symptoms of rheumatoid arthritis (RA) remain even after achieving clinical remission or low disease activity. Impairments to work and societal/daily activity are relevant burdens for patients with RA. However, detailed analyses are rarely performed. For exploring a better strategy aiming at less burden beyond Treat-to-Target strategy, it is essential to evaluate details of subjective symptoms collected as patient-reported-outcomes (PROs) and their relationship to work productivity and activity impairment (WPAI). The purpose of this study was to explore patient-reported outcomes (PROs) related to WPAI in patients with RA who achieved clinical remission.

Methods: The Institute of Rheumatology Rheumatoid Arthritis (IORRA) database is an established cohort database with RA in Tokyo Women’s Medical University since 2000. RA patients ≥18 years who met the 1987 American College of Rheumatology classification criteria for RA and SDAI remission criteria (SDAI<3.3) within the IORRA dataset collected in October 2017 were used for this analysis. Pain-VAS [0–100 mm], patients’ global assessment VAS (Pt-GA) [0–100 mm], Healthcare Assessment Questionnaire-Disability Index (Japanese version; J-HAQ-DI), and duration of morning joint stiffness (MJS) were evaluated. To measure impact on work productivity during the past 7 days, the WPAI-RA instrument (absenteeism, presenteeism, work productivity loss, and daily activity impairment) was used. Spearman’s rank correlation coefficient with 95% confidence interval (95% CI) was calculated to evaluate correlation between each WPAI item and each PRO. To evaluate the degree of contribution of each PRO to WPAI, an ANOVA model was constructed. The contribution of each PRO was calculated based on the sum squares of each PRO divided by total sum squares.

Results: Mean age of the 2,614 patients was 62.4 years; 85.1% were female; and mean DAS28-ESR and SDAI was 2.0 and 1.3, respectively. Mean scores of WPAI were 1.1% for absenteeism (percent work time missed due to RA), 6.5% for presenteeism (percent impairment while working due to RA), 7.4% for work impairment, and 10.2% for activity impairment. Mean pain VAS and Pt-GA were 7.1 and 7.5, respectively, and mean J-HAQ-DI score was 0.3. MJS was reported in 17.6% of patients with a mean duration of 45.3 minutes. Pain VAS showed the strongest positive correlation with each score of WPAI except for absenteeism (Spearman’s rank correlation coefficient [95% CI] 0.52 [0.47, 0.56] for presenteeism, 0.50 [0.45, 0.55] for work impairment, and 0.60 [0.57, 0.63] for activity impairment) (Table 1). MJS contributed the most to absenteeism (18.0%) while pain-VAS contributed the most to presenteeism (57.4%), work productivity loss (51.1%), and daily activity impairment (53.7%) (Table 2). J-HAQ-DI was the second most contributing factor to all scores of WPAI (6.0% for absenteeism, 17.4% for presenteeism, 16.3% for work productivity loss, and 26.0% for daily activity impairment).

Conclusion: Pain-VAS and J-HAQ-DI highly contributed to WPAI. This study indicates that improvement in these PROs may lead to less burden of RA patients in clinical remission.

Correlation coefficient between WPAI and each PRO. Values are Spearman’s rank correlation coefficient [95% confidence interval]. WPAI, Work Productivity and Activity Impairment; PRO, patient-reported outcomes; VAS, visual analogue scale; J-HAQ-DI, Japanese version of Healthcare Assessment Questionnaire-Disability Index; MJS, morning joint stiffness

Contribution to variance in WPAI score. WPAI, Work Productivity and Activity Impairment; RA, Rheumatoid arthritis; BMI, Body Mass Index; TJC, Tender joint count; SJC, Swollen joint count; CRP,C-reactive protein; ESR, Erythrocyte sedimentation rate; Ph-GA, Physician’s global assessment; CCI, Charlson Comorbidity Index; PRO, patient-reported outcomes; VAS, visual analogue scale; Pt-GA, Patient’s global assessment; J-HAQ-DI, Japanese version of Healthcare Assessment Questionnaire-Disability Index; MJS, morning joint stiffness


Disclosure: R. Sakai, Ayumi Pharmaceutical Co. Ltd., 1, Bristol Meyers Squib, 1, Chugai Pharmaceutical Co. Ltd., 1, Nippon Kayaku Co. Ltd., 1, Taisho Toyama Pharmaceutical Co. Ltd., 1, Mitsubishi Tanabe Pharma Corp., 1; E. Tanaka, Abbvie, 1, Asahi Kasei Pharma, 1, Chugai Pharmaceutical Co., Ltd., 1, Eisai Pharmaceutical, 1, Janssen Pharmaceutical K.K., 1, Pfizer, 1, Takeda Pharmaceutical, 1, Astellas Pharmaceutical, 1, Ayumi Pharmaceutical, 1, Eli Lilly Japan K.K., 1, GlaxoSmithKline K.K, 1, Kyowa Pharma Chemical CO., LTD, 1, Mochida Pharmaceutical CO., LTD, 1, Teijin Pharma Ltd., 1; E. Inoue, Bristol-Myers Squibb, 1, Pfizer, 1; M. Sato, Eli Lilly Japan K.K, 1; M. Tanaka, Eli Lilly Japan K.K, 3; K. Ikari, Chugai Pharmaceutical Co., 1, Asahi Kasei Pharma Corporation, 1, Astellas Pharma Incorporated, 1, AbbVie, 1, Ayumi Pharmaceutical Corporation, 1, Bristol Myers Squibb Corporation, Ltd., 1, Chugai Pharmaceutical Co., Ltd., 1, Eisai Pharmaceutical, 1, Eli-Lilly Japan K.K., 1, Janssen Pharmaceutical K.K., 1, Kaken Pharmaceutical Co. Ltd., 1, Mitsubishi Tanabe Pharma Corp., 1, Pfizer Japan Inc., 1, Takeda Pharmaceutical Co. Ltd., 1, Teijin Pharma Ltd, 1, UCB Japan Co. Ltd, 1; A. Taniguchi, None; H. Yamanaka, Chugai Pharmaceutical Co. Ltd., 1, 2, Astellas Pharma Inc., 1, 2, Bristol-Meyers Squibb, 1, 2, Daiichi-Sankyo Co. Ltd, 1, 2, Mitsubishi-Tanabe Pharma Corp., 1, 2, Takeda Pharmaceutical Co. Ltd., 1, 2, Teijin Pharma Ltd., 1, 2, Pfizer Japan Inc, 1, 2, YLbio, 1, 2, Ayumi Pharmaceutical Co. Ltd., 1, Boehringer Ingelheim, 1, AbbVie Japan Co. Ltd, 1, Eisai Co., Ltd, 1, Kaken Pharmaceutical Co., Ltd., 1, Nippon-Shinyaku, 1, Novartis Pharma K. K., 1, Ono Pharmaceutical Co., Ltd, 1, Taisho Toyama Pharmaceutical Co., Ltd., 1, Torii Pharmaceutical Co., Ltd, 1, UCB Japan Co. Ltd, 1; M. Harigai, AbbVie Japan GK, 1, 2, Asahi Kasei Corp., 1, Astellas Pharma Inc., 1, Ayumi Pharmaceutical Co. Ltd., 1, 2, Bristol Myers Squibb Co., Ltd, 1, 2, 3, Chugai Pharmaceutical Co. Ltd., 1, 2, Daiichi-Sankyo, Inc., 1, Eisai Pharmaceutical, 1, 2, Nippon Kayaku Co. Ltd., 1, Mitsubishi Tanabe Pharma Co., 1, Taisho Pharmaceutical Co. Ltd., 1, Takeda Pharmaceutical Co. Ltd., 1, 2, Eli Lilly Japan K.K, 1, Pfizer Japan Inc, 1, AbbVie, 1.

To cite this abstract in AMA style:

Sakai R, Tanaka E, Inoue E, Sato M, Tanaka M, Ikari K, Taniguchi A, Yamanaka H, Harigai M. Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/associations-between-patient-reported-outcomes-and-impairments-of-work-and-activity-in-patients-with-rheumatoid-arthritis-who-achieved-clinical-remission-retrospective-analysis-using-the-iorra-databa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-between-patient-reported-outcomes-and-impairments-of-work-and-activity-in-patients-with-rheumatoid-arthritis-who-achieved-clinical-remission-retrospective-analysis-using-the-iorra-databa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology